Pneumococcal Vaccine Market Analysis from 2022 to 2034 Containing Market Size, Share along with its CAGR, Forecast and Trends

Top Countries — Revenue

USD Million/Billion
Loading…

Market Dynamics of Pneumococcal Vaccine Market Analysis

↑ Growth Drivers

  • Rising prevalence of pneumococcal infections to boost market growth
  • Growing geriatric population to propel market growth
  • Advancements in vaccine technology to drive market growth

↓ Restraints

  • High vaccine costs will limit market growth
  • Long clinical trials and intricate FDA and EMA approval procedures impede the development of vaccines and their introduction into the market

~ Trends

  • Development of next-generation vaccines
  • Expanding adult vaccination programs

Access the full forecast model.

Country-level data · Company profiles · Editable dataset · Analyst consultation included.

Pneumococcal Vaccine Market Analysis — Presence

Geographical Analysis

Click countries to explore
Loading map…

Regional and Country Analysis

Region / Country 2021 (A)2025 (A)2033 (P) CAGR
Globalxxxx$ 8261.9 Million$ 14195.5 Million7%
North Americaxxxx$ 3056.9 Million$ 4684.5 Million5.5%
United Statesxxxx$ 2411.9 Millionxxxx5.3%
Canadaxxxx$ 366.83 Millionxxxx6.3%
Mexicoxxxx$ 278.18 Millionxxxx6%
Europexxxx$ 2395.95 Million$ 3832.8 Million6%
United Kingdomxxxx$ 402.52 Millionxxxx6.8%
Francexxxx$ 220.43 Millionxxxx5.2%
Germanyxxxx$ 474.4 Millionxxxx6.2%
Italyxxxx$ 206.05 Millionxxxx5.4%
Russiaxxxx$ 371.37 Millionxxxx5%
Spainxxxx$ 196.47 Millionxxxx5.1%
Swedenxxxx$ 74.27 Millionxxxx6.1%
Denmarkxxxx$ 50.31 Millionxxxx5.8%
Switzerlandxxxx$ 35.94 Millionxxxx5.7%
Luxembourgxxxx$ 28.75 Millionxxxx6.3%
Rest of Europexxxx$ 335.43 Millionxxxx4.7%
Asia Pacificxxxx$ 1982.86 Million$ 4166.4 Million9.7%
Chinaxxxx$ 832.8 Millionxxxx9.2%
Japanxxxx$ 273.63 Millionxxxx8.2%
South Koreaxxxx$ 237.94 Millionxxxx8.8%
Indiaxxxx$ 198.29 Millionxxxx11.6%
Australiaxxxx$ 103.11 Millionxxxx9%
Singaporexxxx$ 39.66 Millionxxxx10%
Taiwanxxxx$ 77.33 Millionxxxx9.5%
South East Asiaxxxx$ 130.87 Millionxxxx10.5%
Rest of APACxxxx$ 89.23 Millionxxxx9.5%
South Americaxxxx$ 313.95 Million$ 567.8 Million7.7%
Brazilxxxx$ 134.37 Millionxxxx8.3%
Argentinaxxxx$ 52.74 Millionxxxx8.6%
Colombiaxxxx$ 27.94 Millionxxxx7.5%
Peruxxxx$ 25.74 Millionxxxx7.9%
Chilexxxx$ 22.6 Millionxxxx8%
Rest of South Americaxxxx$ 50.55 Millionxxxx6.8%
Middle Eastxxxx$ 330.48 Million$ 624.6 Million8.3%
Qatarxxxx$ 26.44 Millionxxxx7.8%
Saudi Arabiaxxxx$ 116.33 Millionxxxx8.6%
Turkeyxxxx$ 26.44 Millionxxxx8.9%
UAExxxx$ 68.08 Millionxxxx8.8%
Egyptxxxx$ 19.83 Millionxxxx8.1%
Rest of Middle Eastxxxx$ 73.37 Millionxxxx7.5%
Africaxxxx$ 181.76 Million$ 319.4 Million7.3%
Nigeriaxxxx$ 14.54 Millionxxxx7.5%
South Africaxxxx$ 63.98 Millionxxxx8.2%

A = Actual · E = Estimated · P = Projected · 🔒 Locked values require full access. Click headers to sort.

Unlock full regional dataset →

Segmentation Analysis


Market size by (Illustrative, 2025)
Share distribution (2025)

Charts are illustrative — exact values, country-level breakdowns, and full forecast in the paid report. Request a Free Sample PDF.

To learn more about market share and segmentation, request the free sample pages.

Competitor Analysis

Competitive Landscape of the Pneumococcal Vaccines Market

The market for pneumococcal vaccines is extremely competitive, with major manufacturers concentrating on research and development, the introduction of new products, and international growth. Prominent corporations include GlaxoSmithKline (Synflorix), Merck & Co., Inc. (Pneumovax, Vaxneuvance), and Pfizer Inc. (Prevnar series). Government partnerships and new biotech companies further heighten competition. To bolster their position in the burgeoning pneumococcal vaccination industry, businesses are investing in next-generation vaccines, reaching a wider audience, and forming strategic alliances.

Vaxcyte completed the phase-2 clinical study in March 2024 to assess the effectiveness of the 24-valent pneumococcal conjugate vaccine (PCV) candidate VAX-24 in eradicating invasive pneumococcal disease (IPD) in children. https://investors.vaxcyte.com/news-releases/news-release-details/vaxcyte-completes-enrollment-phase-2-study-evaluating-vax-24> In January 2024, The Committee of Medicinal Products Intended for Human Use (CHMP) of the European Medicines Agency (EMA) granted Pfizer Inc. marketing authorization for their 20-valent pneumococcal conjugate vaccine candidate (20vPnC). https://www.pfizer.com/news/announcements/pfizer-receives-positive-chmp-opinion-its-20-valent-pneumococcal-conjugate In October 2023, Lonza and Vaxcyte, Inc. worked together to sign a new commercial manufacturing contract. Vaxcyte intends to increase its commercial manufacturing capability for its PCV candidates with this partnership. https://www.lonza.com/news/2023-10-16-14-00 In April 2023, The FDA approved Pfizer Inc.'s Prevnar 20 to prevent newborns from contracting Invasive Pneumococcal Disease (IPD). https://www.pfizer.com/news/press-release/press-release-detail/us-fda-approves-prevnar-20r-pfizers-20-valent-pneumococcal

Click any bar or cell to request the full company profile
Top Companies (In no particular order)2022 (A)2023 (A)2024 (A)2025 (A)
Serum Institute of India Pvt. Ltd.••• ••• ••• •••
CSL••• ••• ••• •••
Sanofi••• ••• ••• •••
GSK plc••• ••• ••• •••
Merck & Co. Inc.••• ••• ••• •••
Pfizer Inc.••• ••• ••• •••
Walvax Biotechnology Co. Ltd••• ••• ••• •••
Beijing Minhai Biotechnology Co. Ltd.••• ••• ••• •••

We Provide Regional Breakdown of this Companies and Company specific to any Country, Region, Product/ service as well. We cover market share analysis for publicly listed companies as well as privately held companies, subject to data availability.

Request company profile for validation →

Report Scope & Analysis

According to Cognitive Market Research, the global Pneumococcal Vaccines Market size will be USD 8261.9 million in 2025. It will expand at a compound annual growth rate (CAGR) of 7.00% from 2025 to 2033.

  • North America held the major market share for more than 40% of the global revenue with a market size of USD 3056.90 million in 2025 and will grow at a compound annual growth rate (CAGR) of 5.5% from 2025 to 2033.
  • Europe accounted for a market share of over 30% of the global revenue with a market size of USD 2395.95 million.
  • APAC held a market share of around 23% of the global revenue with a market size of USD 1982.86 million in 2025 and will grow at a compound annual growth rate (CAGR) of 9.7% from 2025 to 2033.
  • South America has a market share of more than 5% of the global revenue with a market size of USD 313.95 million in 2025 and will grow at a compound annual growth rate (CAGR) of 7.7% from 2025 to 2033.
  • The Middle East had a market share of around 2% of the global revenue and was estimated at a market size of USD 330.48 million in 2025. and will grow at a compound annual growth rate (CAGR) of 8.3% from 2025 to 2033.
  • Africa had a market share of around 1% of the global revenue and was estimated at a market size of USD 181.76 million in 2025 and will grow at a compound annual growth rate (CAGR) of 7.3% from 2025 to 2033.
  • Synflorix category is the fastest growing segment of the Pneumococcal Vaccines Market

 

Introduction of the Pneumococcal Vaccines Market

The market for pneumococcal vaccinations is centred on those that are intended to guard against infections brought on by Streptococcus pneumoniae, a bacterium that causes meningitis, pneumonia, and septicemia. Particularly in newborns, older people, and immunocompromised people, these vaccinations, such as pneumococcal conjugate vaccines (PCVs) and pneumococcal polysaccharide vaccines (PPSVs), help lower morbidity and mortality. Growing immunization programs, increasing disease prevalence, and developments in next-generation vaccines are the main factors driving market dynamics. However, market expansion is constrained by high vaccine costs, restricted availability in low-income areas, and vaccine reluctance. Global market expansion prospects are presented by growing adult immunization programs, new product advancements, and more government assistance.

In April 2024, Merck announced the findings of the STRIDE-10 phase 3 clinical study, which developed an adult 21-valent pneumococcal conjugate vaccination. https://www.merck.com/news/merck-announces-positive-data-for-v116-an-investigational-21-valent-pneumococcal-conjugate-vaccine-specifically-designed-for-adults/

Analyst Conclusion

Our study will explain complete manufacturing process along with major raw materials required to manufacture end-product. This report helps to make effective decisions determining product position and will assist you to understand opportunities and threats around the globe.

The Pneumococcal Vaccine Market Analysis is witnessing significant growth in the near future.

In 2023, the Synflorix segment accounted for a notable share of the Pneumococcal Vaccine Market Analysis.

Supriya Yadav
Supriya Yadav Verified Analyst
Research Analyst · Cognitive Market Research
LinkedIn Profile Book a free Consultation

Frequently Asked Questions

The global market size for Pneumococcal Vaccines in 2025 is USD 8261.9 million.
The global Pneumococcal Vaccines Market is expected to grow with a CAGR of 7.00% over the projected period.
North America held a significant global Pneumococcal Vaccines Market revenue share in 2025.
Asia-Pacific will witness the fastest growth of the global Pneumococcal Vaccines Market over the coming years.
The US had the most significant global Pneumococcal Vaccines Market revenue share in 2025.
The main driver of the growth of the Pneumococcal Vaccines Market is the higher demand for immunization in war-torn and refugee-affected regions and the Increased use of AI and big data in vaccine distribution and monitoring.
The Public Authorities category dominates the market.

★ Reviews

Rate this report

Pneumococcal Vaccine Market Analysis — Table of Contents

Disclaimer:
  • This is just a redacted sample pages of the actual deliverable report and only for representative purposes
  • Charts/Graphs/Numbers/data are only for Representative purposes and do not depict actual statistics.
  • The table of Contents differs according to the user License selection. Current Displayed TOC is for the Corporate User License Report Edition. TOC Customization options: Add or Remove section/s Or chapter/s from the report.
  • Specific Tables, Graphs, Sections, and Chapters can be ordered at a discounted price.
  • If applicable; On Request Volume Data will also be provided (at an Additional Cost).

Product Type Outlook: Synflorix, Pediatric, Adult, Prevenar-13, Pediatric, Adult, PCV 13 (pipeline), Pediatric, Adult, V114 (Merck), Pediatric, Adult, PCV-20 (Pfizer), Pediatric, Adult, PCV-10 (SII), Pediatric, Adult, PPSV-23, Pediatric, Adult
Distribution Channel Outlook: Wholesalers (pharmacy channel), Specialized Companies, Public Authorities, Others
Sector Outlook: Public, Private
List of Competitors Serum Institute of India Pvt. Ltd., CSL, Sanofi, GSK plc, Merck & Co. Inc., Pfizer Inc., Walvax Biotechnology Co. Ltd, Beijing Minhai Biotechnology Co. Ltd.

  • 1.1 Top Competitors Analysis

    • (Subject to Data Availability (Private Players))

      1.1.1 Global Pneumococcal Vaccine Market Analysis by Key Players
    • 1.1.2 Top Players Ranking 2024
    • 1.1.3 New Product Launch Analysis
    • 1.1.4 Industry Mergers and Acquisition Analysis
  • 1.2 Company Profile (Data Subject to Availability) Sample Format

    • Data Subject to Availability as we consider Top competitors and their market share will be delivered.

      1.2.1 Serum Institute of India Pvt. Ltd.
      • 1.2.1.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
      • 1.2.1.2 Business Overview
      • 1.2.1.3 Financials (Subject to data availability)
      • 1.2.1.4 R&D Investment (Subject to data availability)
      • 1.2.1.5 Product Types Specification
      • 1.2.1.6 Business Strategy
      • 1.2.1.7 Recent Developments
      • 1.2.1.8 Management Change
      • 1.2.1.9 S.W.O.T Analysis

    • Data Subject to Availability as we consider Top competitors and their market share will be delivered.

      1.2.2 CSL
      • 1.2.2.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
      • 1.2.2.2 Business Overview
      • 1.2.2.3 Financials (Subject to data availability)
      • 1.2.2.4 R&D Investment (Subject to data availability)
      • 1.2.2.5 Product Types Specification
      • 1.2.2.6 Business Strategy
      • 1.2.2.7 Recent Developments
      • 1.2.2.8 Management Change
      • 1.2.2.9 S.W.O.T Analysis

    • Data Subject to Availability as we consider Top competitors and their market share will be delivered.

      1.2.3 Sanofi
      • 1.2.3.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
      • 1.2.3.2 Business Overview
      • 1.2.3.3 Financials (Subject to data availability)
      • 1.2.3.4 R&D Investment (Subject to data availability)
      • 1.2.3.5 Product Types Specification
      • 1.2.3.6 Business Strategy
      • 1.2.3.7 Recent Developments
      • 1.2.3.8 Management Change
      • 1.2.3.9 S.W.O.T Analysis

    • Data Subject to Availability as we consider Top competitors and their market share will be delivered.

      1.2.4 GSK plc
      • 1.2.4.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
      • 1.2.4.2 Business Overview
      • 1.2.4.3 Financials (Subject to data availability)
      • 1.2.4.4 R&D Investment (Subject to data availability)
      • 1.2.4.5 Product Types Specification
      • 1.2.4.6 Business Strategy
      • 1.2.4.7 Recent Developments
      • 1.2.4.8 Management Change
      • 1.2.4.9 S.W.O.T Analysis

    • Data Subject to Availability as we consider Top competitors and their market share will be delivered.

      1.2.5 Merck & Co. Inc.
      • 1.2.5.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
      • 1.2.5.2 Business Overview
      • 1.2.5.3 Financials (Subject to data availability)
      • 1.2.5.4 R&D Investment (Subject to data availability)
      • 1.2.5.5 Product Types Specification
      • 1.2.5.6 Business Strategy
      • 1.2.5.7 Recent Developments
      • 1.2.5.8 Management Change
      • 1.2.5.9 S.W.O.T Analysis

    • Data Subject to Availability as we consider Top competitors and their market share will be delivered.

      1.2.6 Pfizer Inc.
      • 1.2.6.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
      • 1.2.6.2 Business Overview
      • 1.2.6.3 Financials (Subject to data availability)
      • 1.2.6.4 R&D Investment (Subject to data availability)
      • 1.2.6.5 Product Types Specification
      • 1.2.6.6 Business Strategy
      • 1.2.6.7 Recent Developments
      • 1.2.6.8 Management Change
      • 1.2.6.9 S.W.O.T Analysis

    • Data Subject to Availability as we consider Top competitors and their market share will be delivered.

      1.2.7 Walvax Biotechnology Co. Ltd
      • 1.2.7.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
      • 1.2.7.2 Business Overview
      • 1.2.7.3 Financials (Subject to data availability)
      • 1.2.7.4 R&D Investment (Subject to data availability)
      • 1.2.7.5 Product Types Specification
      • 1.2.7.6 Business Strategy
      • 1.2.7.7 Recent Developments
      • 1.2.7.8 Management Change
      • 1.2.7.9 S.W.O.T Analysis

    • Data Subject to Availability as we consider Top competitors and their market share will be delivered.

      1.2.8 Beijing Minhai Biotechnology Co. Ltd.
      • 1.2.8.1 Company Basic Information, Manufacturing Base, Sales Area, and Competitors
      • 1.2.8.2 Business Overview
      • 1.2.8.3 Financials (Subject to data availability)
      • 1.2.8.4 R&D Investment (Subject to data availability)
      • 1.2.8.5 Product Types Specification
      • 1.2.8.6 Business Strategy
      • 1.2.8.7 Recent Developments
      • 1.2.8.8 Management Change
      • 1.2.8.9 S.W.O.T Analysis

  • 2.1 Global Pneumococcal Vaccine Market Analysis
  • 2.2 Global Pneumococcal Vaccine Market Analysis by Region
  • 2.3 Global Pneumococcal Vaccine Market Analysis by Product Type Outlook:
  • 2.4 Global Pneumococcal Vaccine Market Analysis by Distribution Channel Outlook:
  • 2.5 Global Pneumococcal Vaccine Market Analysis by Sector Outlook:
  • 2.6 Global Pneumococcal Vaccine Market Analysis by Key Players

  • 3.1 North America Pneumococcal Vaccine Market Analysis
  • 3.2 North America Pneumococcal Vaccine Market Analysis by Country
  • 3.3 North America Pneumococcal Vaccine Market Analysis by Product Type Outlook:
  • 3.4 North America Pneumococcal Vaccine Market Analysis by Distribution Channel Outlook:
  • 3.5 North America Pneumococcal Vaccine Market Analysis by Sector Outlook:
  • 3.6 North America Pneumococcal Vaccine Market Analysis by Key Players

  • 4.1 Europe Pneumococcal Vaccine Market Analysis
  • 4.2 Europe Pneumococcal Vaccine Market Analysis by Country
  • 4.3 Europe Pneumococcal Vaccine Market Analysis by Product Type Outlook:
  • 4.4 Europe Pneumococcal Vaccine Market Analysis by Distribution Channel Outlook:
  • 4.5 Europe Pneumococcal Vaccine Market Analysis by Sector Outlook:
  • 4.6 Europe Pneumococcal Vaccine Market Analysis by Key Players

  • 5.1 Asia Pacific Pneumococcal Vaccine Market Analysis
  • 5.2 Asia Pacific Pneumococcal Vaccine Market Analysis by Country
  • 5.3 Asia Pacific Pneumococcal Vaccine Market Analysis by Product Type Outlook:
  • 5.4 Asia Pacific Pneumococcal Vaccine Market Analysis by Distribution Channel Outlook:
  • 5.5 Asia Pacific Pneumococcal Vaccine Market Analysis by Sector Outlook:
  • 5.6 Asia Pacific Pneumococcal Vaccine Market Analysis by Key Players

  • 6.1 South America Pneumococcal Vaccine Market Analysis
  • 6.2 South America Pneumococcal Vaccine Market Analysis by Country
  • 6.3 South America Pneumococcal Vaccine Market Analysis by Product Type Outlook:
  • 6.4 South America Pneumococcal Vaccine Market Analysis by Distribution Channel Outlook:
  • 6.5 South America Pneumococcal Vaccine Market Analysis by Sector Outlook:
  • 6.6 South America Pneumococcal Vaccine Market Analysis by Key Players

  • 7.1 Middle East Pneumococcal Vaccine Market Analysis
  • 7.2 Middle East Pneumococcal Vaccine Market Analysis by Country
  • 7.3 Middle East Pneumococcal Vaccine Market Analysis by Product Type Outlook:
  • 7.4 Middle East Pneumococcal Vaccine Market Analysis by Distribution Channel Outlook:
  • 7.5 Middle East Pneumococcal Vaccine Market Analysis by Sector Outlook:
  • 7.6 Middle East Pneumococcal Vaccine Market Analysis by Key Players

  • 8.1 Africa Pneumococcal Vaccine Market Analysis
  • 8.2 Africa Pneumococcal Vaccine Market Analysis by Country
  • 8.3 Africa Pneumococcal Vaccine Market Analysis by Product Type Outlook:
  • 8.4 Africa Pneumococcal Vaccine Market Analysis by Distribution Channel Outlook:
  • 8.5 Africa Pneumococcal Vaccine Market Analysis by Sector Outlook:
  • 8.6 Africa Pneumococcal Vaccine Market Analysis by Key Players

  • 9.1 Synflorix
    • 9.1.1 Global Synflorix Market
    • 9.1.2 Global Synflorix Market by Region
  • 9.2 Pediatric
    • 9.2.1 Global Pediatric Market
    • 9.2.2 Global Pediatric Market by Region
  • 9.3 Adult
    • 9.3.1 Global Adult Market
    • 9.3.2 Global Adult Market by Region
  • 9.4 Prevenar-13
    • 9.4.1 Global Prevenar-13 Market
    • 9.4.2 Global Prevenar-13 Market by Region
  • 9.5 Pediatric
    • 9.5.1 Global Pediatric Market
    • 9.5.2 Global Pediatric Market by Region
  • 9.6 Adult
    • 9.6.1 Global Adult Market
    • 9.6.2 Global Adult Market by Region
  • 9.7 PCV 13 (pipeline)
    • 9.7.1 Global PCV 13 (pipeline) Market
    • 9.7.2 Global PCV 13 (pipeline) Market by Region
  • 9.8 Pediatric
    • 9.8.1 Global Pediatric Market
    • 9.8.2 Global Pediatric Market by Region
  • 9.9 Adult
    • 9.9.1 Global Adult Market
    • 9.9.2 Global Adult Market by Region
  • 9.10 V114 (Merck)
    • 9.10.1 Global V114 (Merck) Market
    • 9.10.2 Global V114 (Merck) Market by Region
  • 9.11 Pediatric
    • 9.11.1 Global Pediatric Market
    • 9.11.2 Global Pediatric Market by Region
  • 9.12 Adult
    • 9.12.1 Global Adult Market
    • 9.12.2 Global Adult Market by Region
  • 9.13 PCV-20 (Pfizer)
    • 9.13.1 Global PCV-20 (Pfizer) Market
    • 9.13.2 Global PCV-20 (Pfizer) Market by Region
  • 9.14 Pediatric
    • 9.14.1 Global Pediatric Market
    • 9.14.2 Global Pediatric Market by Region
  • 9.15 Adult
    • 9.15.1 Global Adult Market
    • 9.15.2 Global Adult Market by Region
  • 9.16 PCV-10 (SII)
    • 9.16.1 Global PCV-10 (SII) Market
    • 9.16.2 Global PCV-10 (SII) Market by Region
  • 9.17 Pediatric
    • 9.17.1 Global Pediatric Market
    • 9.17.2 Global Pediatric Market by Region
  • 9.18 Adult
    • 9.18.1 Global Adult Market
    • 9.18.2 Global Adult Market by Region
  • 9.19 PPSV-23
    • 9.19.1 Global PPSV-23 Market
    • 9.19.2 Global PPSV-23 Market by Region
  • 9.20 Pediatric
    • 9.20.1 Global Pediatric Market
    • 9.20.2 Global Pediatric Market by Region
  • 9.21 Adult
    • 9.21.1 Global Adult Market
    • 9.21.2 Global Adult Market by Region

  • 10.1 Wholesalers (pharmacy channel)
    • 10.1.1 Global Wholesalers (pharmacy channel) Market
    • 10.1.2 Global Wholesalers (pharmacy channel) Market by Region
  • 10.2 Specialized Companies
    • 10.2.1 Global Specialized Companies Market
    • 10.2.2 Global Specialized Companies Market by Region
  • 10.3 Public Authorities
    • 10.3.1 Global Public Authorities Market
    • 10.3.2 Global Public Authorities Market by Region
  • 10.4 Others
    • 10.4.1 Global Others Market
    • 10.4.2 Global Others Market by Region

  • 11.1 Public
    • 11.1.1 Global Public Market
    • 11.1.2 Global Public Market by Region
  • 11.2 Private
    • 11.2.1 Global Private Market
    • 11.2.2 Global Private Market by Region

  • 12.1 Market Drivers
  • 12.2 Market Restraints
  • 12.3 Market Trends
  • 12.4 Market Opportunity
  • 12.5 Technological Road Map (Subject to Data Availability)
  • 12.6 Product Life Cycle (Subject to Data Availability)
  • 12.7 Customer and Buyer Behavior Analysis
    • 12.7.1 Consumer Demographics and Target Audience Assessment
    • 12.7.2 Digital Engagement, Customer Experience & Relationship Analysis
    • 12.7.3 Customer Buying Behavior & Purchase Decision Analysis
    • 12.7.4 Vendor Selection, Supplier Preferences & Future Demand Trends
    • 12.7.5 Pricing, Affordability & Value Perception Analysis
    • 12.7.6 Customer Segmentation & Demand Pattern Analysis
  • 12.8 PESTEL Analysis
    • 12.8.1 Political Factors
    • 12.8.2 Economic Factors
    • 12.8.3 Social Factors
    • 12.8.4 Technological Factors
    • 12.8.5 Legal Factors
    • 12.8.6 Environmental Factors
  • 12.9 Industrial Chain Analysis (Subject to Data Availability)
    • 12.9.1 Industry Chain Analysis
    • 12.9.2 Manufacturing Cost Analysis
    • 12.9.3 Supply Side Analysis
      • 12.9.3.1 Raw Material Analysis
      • 12.9.3.2 Raw Material Procurement Analysis
      • 12.9.3.3 Raw Material Price Trend Analysis
  • 12.10 Porter’s Five Forces Analysis
    • 12.10.1 Bargaining Power of Suppliers
    • 12.10.2 Bargaining Power of Buyers
    • 12.10.3 Threat of New Entrants
    • 12.10.4 Threat of Substitutes
    • 12.10.5 Degree of Competition
  • 12.11 Patent Analysis (Subject to Data Availability)
  • 12.12 ESG Analysis
  • 12.13 Geopolitical Outlook
    • 12.13.1 Global Power Realignment & Strategic Alliances
    • 12.13.2 Geopolitical Risk Landscape & Conflict Hotspots
    • 12.13.3 International Trade Relations & Market Access Environment
    • 12.13.4 Regulatory & Policy Shifts Impacting Cross-Border Operations
    • 12.13.5 Supply Chain Resilience, Localization & Resource Nationalism
    • 12.13.6 Technology Sovereignty & Digital Geopolitics
    • 12.13.7 Strategic Implications for Investment, Growth & Market Entry

  • This chapter isn't just about technology; it’s about certainty. We show you how AI is being used in leading industries so you can apply those same 'High-Speed' and 'High-Accuracy' principles to your own market strategy

    12.14 AI & Market Transformation
    • 12.14.1 Competitive Landscape Disruption & Strategic Shifts
    • 12.14.2 AI-Driven Transformation of Industry Value Chain
    • 12.14.3 Evolution of Business Models & Revenue Streams
    • 12.14.4 AI-Driven Product, Service & Innovation Transformation
    • 12.14.5 Customer Behavior, AI Adoption & Future Market Evolution

  • 13.1 Country 1
    • 13.2 Country 2
    • 13.3 Country 3
    • 13.4 Country 4
    • 13.5 Country 5
    • 13.6 Country 6
    • 13.7 Country 7
    • 13.8 Country 8
    • 13.9 Country 9
    • 13.10 Country 10

    • 14.1 Key Takeaways

    • Here the analyst will summarize the content of entire report and will share his view point on the current industry scenario and how the market is expected to perform in the near future. The points shared by the analyst are based on his/her detailed in-depth understanding of the market during the course of this report study. You will be provided exclusive rights to interact with the concerned analyst for unlimited time pre purchase as well as post purchase of the report.

      14.2 Analyst Point of View
    • 14.3 Assumptions and Acronyms

    • 15.1 Primary Data Collection
      • 15.1.1 Steps for Primary Data Collection
        • 15.1.1.1 Identification of KOL
      • 15.1.2 Backward Integration
      • 15.1.3 Forward Integration
      • 15.1.4 How Primary Research Help Us
      • 15.1.5 Modes of Primary Research
    • 15.2 Secondary Research
      • 15.2.1 How Secondary Research Help Us
      • 15.2.2 Sources of Secondary Research
    • 15.3 Data Validation
      • 15.3.1 Data Triangulation
    • 15.4 Data Representation

    Athenaeum AI Dashboard

    Research Framework · 70:30 Primary:Secondary

    Our Proprietary Methodology

    Cognitive Market Research and Consulting "The Full Truth" methodology — a rigorous triangulation process that combines primary research, secondary validation, and expert calibration. Implemented by Supriya Yadav and team for the Pneumococcal Vaccine Market Analysis Market analysis.

    01

    Primary Intelligence Gathering

    Direct interviews with 50+ industry stakeholders including manufacturers, distributors, end-users, and regulatory bodies across all six regions.

    02

    Secondary Data Triangulation

    Cross-referencing against trade databases, customs records, financial filings, patent databases, and verified industry publications.

    03

    Expert Validation Protocol

    Each data point undergoes validation by minimum two independent domain experts with 15+ years of industry experience.

    04

    Athenaeum AI Processing

    Our proprietary AI platform aggregates, normalizes, and identifies patterns across 10,000+ data points to surface non-obvious insights.

    05

    Editorial & QA Review

    Final review by senior analysts ensures accuracy, coherence, and actionability of all insights and recommendations.

    Data Assurance Metrics
    Data Points Validated 10,400+
    Expert Interviews 54
    Countries Covered 39+
    Company Profiles 8+
    Forecast Accuracy (Historical) 94.2%
    Report Pages 250+
    Analytical Coverage
    Market Sizing Revenue Forecast CAGR Analysis Competitor Benchmarking SWOT Porter's Analysis PESTEL Value Chain ESG Analysis Tariff Impact Patent Mapping Tech Trends

    To maintain the integrity of our proprietary methodology and protect our elite expert network, specific source disclosures are reserved for full-access partners. Our research framework is anchored by a 70:30 primary-to-secondary ratio, ensuring your strategy is driven by real-time market intelligence rather than recycled, publicly available, or AI-generated data. Every deliverable includes an exhaustive source directory and grants direct analyst access.

    Latest News about Pneumococcal Vaccine Market

     24 Jun 2024 health.economictimes.indiatimes.com

    US FDA approves Merck's pneumococcal vaccine for adults

    According to Merck, the FDA in the US has authorized its next-generation vaccine to guard against pneumococcal illness in adults. Pneumonia can result from infections caused by the illness in the lungs, among other sections of the body. The bacterium that may cause such diseases comes in around a hundred different types. In a range of adult populations across trials, Merck's vaccine, marketed under the trade name Capvaxive, assisted in eliciting an immune response against all 21 serotypes, or varieties of the bacterium, that the injection targeted. The vaccine costs USD 287 a dose at wholesale, according to the drugmaker, but most people will probably be able to get it for free if the advisors at the Centres for Disease Control and Prevention routinely suggest it. Currently, Merck offers two authorized pneumococcal vaccinations: Pneumovax 23 for people 50 years of age and above, as well as Vaxneuvance for those six weeks of age and older who are at an increased risk of contracting the illness.

    Read the source

    Sources from the Pharma & Healthcare Industry

    How We Serve You

    The Three Pillars of End-to-End Market Research Services

    We don't just hand over data. We partner with your team across three integrated service lines — each designed to give you decision-grade intelligence on the Pneumococcal Vaccine Market Analysis market.

    Service 01

    Market Survey

    B2B B2C

    Structured primary research across both B2B and B2C channels. We design and execute custom surveys targeting manufacturers, distributors, procurement heads, and end-consumers in the pneumococcal vaccine market analysis ecosystem — validated by our global panel of 10,000+ industrial respondents.

    What's Included
    • Buyer intent & sentiment analysis
    • Purchase cycle mapping
    • Price sensitivity research
    • Channel preference profiling
    • Competitive perception study
    Most Requested
    Service 02

    Customized Market Data & Reports

    Custom Ready Report

    Choose from our ready-to-access 8th Edition report or commission a fully customized dataset tailored to your exact strategic questions. Cross-splits, custom geographies, proprietary segmentation — we build the intelligence asset your board actually needs.

    What's Included
    • Ready syndicate report (250+ pages)
    • Custom data scope & segmentation
    • Excel quantitative models
    • Board-ready PPT with key findings
    • Secure cloud portal access
    Service 03

    Strategic Consultation

    With Survey With Report

    Every survey and every report comes with dedicated analyst consultation. Our senior research team walks your leadership through findings, answers strategic questions in real-time, and helps translate data into your next board presentation or investment thesis.

    What's Included
    • Dedicated analyst assigned to you
    • Live walkthrough of findings
    • Strategic Q&A sessions
    • Go-to-market recommendations
    • NDA-protected engagement

    Customize This Report

    Tell us the specific segments, regions, or companies you need — and we will tailor the deliverable to your requirements.